Midi Health, MD-Led Platform

Midi Health is a California-based women's midlife healthcare company founded in 2021 by Joanna Strober, a venture capitalist who became frustrated with the lack of coordinated care available to women navigating perimenopause. The company was built on a central clinical insight: the health changes that cluster in a woman's 40s and 50s — irregular periods, mood shifts, weight redistribution, sleep disruption, thyroid dysfunction, and cardiovascular risk elevation — are interconnected and hormonally driven, yet are routinely managed by separate specialists who rarely communicate. Midi attempts to address this fragmentation with a single virtual care team that treats the full constellation of midlife health issues. Midi's scope is broader than most menopause telehealth platforms. In addition to hormone replacement therapy for hot flashes, night sweats, and genitourinary symptoms, Midi clinicians manage hypothyroidism, anxiety and depression in perimenopausal women, weight-related metabolic changes, and cardiovascular risk factors like elevated cholesterol and blood pressure. This breadth is clinically grounded: estrogen decline during perimenopause directly affects thyroid function, mood regulation, lipid profiles, and bone density, making a siloed approach medically incomplete for many patients. The company is in-network with most PPO plans — including Aetna, Blue Cross Blue Shield, and United Healthcare — across all 50 states, a rare achievement for a women's telehealth startup. Most insured patients pay an average of $50 per visit, removing the price barrier that limits access to cash-pay platforms for many midlife women. Midi does not accept Medicaid or Medicare, which limits access for lower-income and older patients. In 2024, Midi announced a collaboration with Mount Sinai Health System in New York, lending academic medical credibility to its clinical protocols. The following year, the company launched AgeWell, an insurance-covered longevity program that includes annual diagnostic visits, labs, and targeted preventive care for postmenopausal women. In the same period, Midi raised additional funding that it indicated would be used to expand its clinician network and invest in proprietary clinical decision support tools. Midi employs both physicians and advanced practice providers, with all clinicians receiving specialized training in menopause medicine and midlife women's health. The care model is designed around longer appointments than a standard primary care visit — sufficient time to work through the multi-symptom presentations that are common in perimenopause — and continuous access to secure messaging between scheduled visits. The company was built on a central clinical insight: the health changes that cluster in a woman's 40s and 50s — irregular periods, mood shifts, weight redistribution, sleep disruption, thyroid dysfunction, and cardiovascular risk elevation — are interconnected and hormonally driven, yet are routinely managed by separate specialists who rarely communicate. Midi attempts to address this fragmentation with a single virtual care team that treats the full constellation of midlife health issues. Midi's scope is broader than most menopause telehealth platforms. In addition to hormone replacement therapy for hot flashes, night sweats, and genitourinary symptoms, Midi clinicians manage hypothyroidism, anxiety and depression in perimenopausal women, weight-related metabolic changes, and cardiovascular risk factors like elevated cholesterol and blood pressure. This breadth is clinically grounded: estrogen decline during perimenopause directly affects thyroid function, mood regulation, lipid profiles, and bone density, making a siloed approach medically incomplete for many patients. The company is in-network with most PPO plans — including Aetna, Blue Cross Blue Shield, and United Healthcare — across all 50 states, a rare achievement for a women's telehealth startup. Most insured patients pay an average of $50 per visit, removing the price barrier that limits access to cash-pay platforms for many midlife women. Midi does not accept Medicaid or Medicare, which limits access for lower-income and older patients. In 2024, Midi announced a collaboration with Mount Sinai Health System in New York, lending academic medical credibility to its clinical protocols. The following year, the company launched AgeWell, an insurance-covered longevity program that includes annual diagnostic visits, labs, and targeted preventive care for postmenopausal women. In the same period, Midi raised additional funding that it indicated would be used to expand its clinician network and invest in proprietary clinical decision support tools. Midi employs both physicians and advanced practice providers, with all clinicians receiving specialized training in menopause medicine and midlife women's health. The care model is designed around longer appointments than a standard primary care visit — sufficient time to work through the multi-symptom presentations that are common in perimenopause — and continuous access to secure messaging between scheduled visits.